NCT01093417

Brief Summary

The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 24, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 25, 2010

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

February 29, 2012

Completed
Last Updated

July 14, 2016

Status Verified

June 1, 2016

Enrollment Period

9 months

First QC Date

March 24, 2010

Results QC Date

January 28, 2012

Last Update Submit

June 14, 2016

Conditions

Keywords

Vitamin DHuman Immunodeficiency Virus (HIV)Complementary Therapies

Outcome Measures

Primary Outcomes (1)

  • Change in Endothelial Function

    Endothelial function measured by flow mediated brachial artery dilation

    Baseline and 12 weeks

Secondary Outcomes (1)

  • Change in Serum 25-hydroxyvitamin D Concentration in Both Groups

    Baseline and 12 weeks

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Participants that have been randomized into this arm will receive placebo pills.

Other: Placebo

Vitamin D 4000 IU

ACTIVE COMPARATOR

Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.

Drug: Vitamin D

Interventions

Vitamin D 4000 IU will be administered to enrollees on the active comparator arm

Also known as: Calciferol
Vitamin D 4000 IU
PlaceboOTHER

Placebo pills will be administered to enrollees in this arm

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HIV infected
  • HIV-RNA \< 400 copies/ml at study entry and for 12 wks. prior
  • hydroxyvitamin D level \<20
  • On a stable anti-retroviral (ARV) regimen for at least 12 weeks prior to study entry

You may not qualify if:

  • Pregnancy or Breast Feeding
  • Diabetes
  • Creatinine Clearance \<50
  • Any active infectious or inflammatory condition
  • aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 within 6 months prior to study entry

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals of Cleveland Case Medical Center

Cleveland, Ohio, 44106, United States

Location

Related Publications (1)

  • Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, Labbato DE, Storer N, Tangpricha V, McComsey GA. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17(4):613-21. doi: 10.3851/IMP1983. Epub 2011 Nov 17.

MeSH Terms

Conditions

Acquired Immunodeficiency SyndromeVitamin D DeficiencyHIV Infections

Interventions

Vitamin DCholecalciferol

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsCholestenesCholestanesSterolsMembrane LipidsLipids

Results Point of Contact

Title
Grace McComsey, MD
Organization
University Hospitals Case Medical Center

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, Peds ID, Rheumatology and Global Health

Study Record Dates

First Submitted

March 24, 2010

First Posted

March 25, 2010

Study Start

January 1, 2010

Primary Completion

October 1, 2010

Study Completion

October 1, 2010

Last Updated

July 14, 2016

Results First Posted

February 29, 2012

Record last verified: 2016-06

Locations